We are live on ! Find out more
NUVL

Nuvalent

Delisted

NUVL was delisted on the 14th of July, 2026.

109 hedge funds and large institutions have $2.33B invested in Nuvalent in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,275% more call options, than puts

Call options by funds: $215K | Put options by funds: $4K

250% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 8

65% more capital invested

Capital invested by funds: $1.41B → $2.33B (+$920M)

22% more funds holding

Funds holding: 89109 (+20)

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

12% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 33

1.86% more ownership

Funds ownership: 105.68%107.54% (+1.9%)

Holders
109
Holders Change
+20
Holders Change %
+22.47%
% of All Funds
1.71%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
28
Increased
37
Reduced
33
Closed
8
Calls
$215K
Puts
$4K
Net Calls
+$211K
Net Calls Change
-$16.6M

NUVL Hedge Fund Activity: Q2 2023 in Review

109 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Nuvalent (NUVL) for Q2 2023, worth a combined $2.33B — up 65% from $1.41B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NUVL positions and 8 closed out — a net gain of 20 holders — while 37 added to existing stakes and 33 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $42.4M. The largest seller was JP Morgan Chase, cutting an estimated $14.4M.

  • 109 institutional investors held Nuvalent (NUVL) as of Q2 2023, up from 89 in Q1 2023.
  • Funds reported $2.33B of Nuvalent stock for Q2 2023, up 65% quarter-over-quarter.
  • 28 funds opened new Nuvalent positions in Q2 2023 and 8 closed out, a net change of +20 holders.
  • The largest Nuvalent buyer in Q2 2023 was Paradigm Biocapital Advisors, an estimated $42.4M added.
  • The largest Nuvalent seller in Q2 2023 was JP Morgan Chase, an estimated $14.4M sold.

Based on aggregated 13F filings for Q2 2023.